Compare Adaptive Biotechnologies Corp (ADPT) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while iShares 7-10 Year Treasury Bond ETF trades at $93.49. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | IEF | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $97.99 |
52-Week Low | $10.24 | $93.11 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IEF, a US stock, trades at $93.7, down 0.45% over 24 hours, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments scheduled for mid-2026. The stock lacks key valuation and profitability ratios in the provided data, limiting fundamental assessment. News highlights bond market dynamics and Federal Reserve policy uncertainty influencing sentiment.
The outlook for IEF is cautious due to bearish technical indicators and macroeconomic headwinds like potential rate hikes. Investment opportunities may arise from dividend distributions, but risks include market volatility and Fed policy shifts. Investors should weigh technical weakness against income potential in a fluctuating interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
